82%
of Lindus sponsor trials have completed enrollment on or ahead of timeline
[1]
Lindus Therapeutics
Building the next generation of biopharma
We are in-licensing clinical-stage assets to develop through our own integrated clinical trial operating model. Built for biopharma looking for a partner that can take a program further, faster.
45+
completed trials across a broad therapeutic area spread
120
full-time employees across the US and Europe
[1] Measured against all 28 trials that completed enrollment within the past 3 years, where Lindus was responsible for enrollment.
About us
Leveraging our trial execution capability
to build an internal asset portfolio
Lindus was founded as a technology-first clinical research organization. We are extending into asset development, acquiring clinical-stage therapeutics and developing them internally using the same infrastructure that delivered 82% of our sponsor trials on or ahead of timeline.
Why Lindus
A partner that can execute on what
you've built
01
Proven in-house trial execution
A track record of delivering trials on time and on budget across 45+ completed programs. Your asset is developed by the same team that designs and executes it. No external CRO layer, no handoff, no misaligned incentives.
02
Faster timeline to readout
Centralized patient enrollment infrastructure combines AI-powered EHR querying, digital pre-screening, and patient concierge. This reduces screen failures and compresses enrollment timelines. Our trial platform enables faster close-out and analysis.
03
Optimized trial designs
Our technology platform and international footprint enable trial designs that aren't practical with standard biopharma partners: multi-country trials, multi-indication programs, and adaptive approaches built to the asset.
Our approach
Deal structures that work for both sides
We structure deals so that value accrues to the originating company as the program progresses. Our preference is for transaction structures that align incentives around clinical and commercial milestones rather than maximizing upfront consideration.
We are pragmatic about deal shape. Exclusive and non-exclusive licenses, territory splits, option agreements, and co-development are all on the table. We move quickly on assets that fit our therapeutic focus and operational model.
Team and advisors
Leadership with deep operational and
scientific expertise
Leadership
.jpeg)
Meri Beckwith
Co-Founder and CEO
Former life sciences and healthtech venture capital investor. Co-founded Lindus after seeing CROs repeatedly fail to deliver trials on time and on budget. MSc Biology, University of Oxford.
.jpeg)
Michael Young
Co-Founder
Previously Special Adviser to the UK Prime Minister on life sciences. Before government, advised healthcare clients at McKinsey & Company and L.E.K. Consulting.
Dr. Luke Twelves
CMO
Physician with nearly three decades of clinical and leadership experience. Former CEO of Omnes Healthcare. Trained at Oxford, Cambridge, and Durham (MBA).
Sean Sheppard
VP Corporate Development
Previously Director of BD and Investments at AtaiBeckley, leading licensing, M&A and equity deals across its clinical-stage neuroscience portfolio. Began his career at L.E.K. Consulting and holds Natural Sciences degrees from the University of Cambridge.
Advisors
Dr. Robert Langer
Strategic Advisor
Co-founder of Moderna and 40+ biopharma companies. Institute Professor at MIT. Holds 1,400+ patents and is one of three living individuals to receive both the US National Medal of Science and the National Medal of Technology and Innovation.
Dr. Tim Garnett
Strategic Advisor
Former Chief Medical Officer and SVP at Eli Lilly (2008-2021). Oversaw regulatory affairs, patient safety, and global clinical development across the US, Europe, China, and Japan.
Dr. Alessandro Falcone
Strategic Advisor
Regional Head of JLABS Singapore for Johnson & Johnson. Previously Executive Director of Breast Cancer Oncology R&D Clinical Development Strategy at AstraZeneca, leading programs for Enhertu, Lynparza, and Imfinzi.
